Endonovo
Therapeutics’ (OTCQB: ENDV) proprietary SofPulse(R) flagship device
recently received a glowing review for minimizing pain from a foot-and-ankle
specialist in Ohio who underwent tendon surgery. An article discussing the
company reads, “In a homemade video, Dr. Jane Graenber, DPM, of the Foot and
Ankle Wellness Center in Delaware, Ohio, attests that Endonovo’s SofPulse(R)
electroceutical device has helped her to remain generally pain free a day after
the tendon surgery, such that she says she has only used three doses of Tylenol
for relief (no prescription pain pills) during the interim since her procedure
(http://ibn.fm/H2n5X). . . .
‘This device is putting out a micro-current to my surgical area every two
hours. . . . And it’s taken care of the pain, and I’m sitting here very
comfortably,’ Graenber states in the video. ‘At our practice, we may be
starting to include this postoperatively as an option to reduce pain. This was
a pretty big surgery, and I’m really very comfortable. So I’m giving credit to
a good surgeon but also a new device that may revolutionize pain (treatment)
after surgery.’”
To view the full article, visit http://ibn.fm/jKNzp
About Endonovo Therapeutics
Endonovo Therapeutics is a commercial-stage developer of
noninvasive, wearable Electroceuticals(R) therapeutic devices. The company’s
current portfolio of commercial and clinical-stage wearable Electroceuticals(R)
therapeutic devices addresses wound healing, pain, postsurgical pain and edema,
cardiovascular disease, chronic kidney disease, and central nervous system
(“CNS”) disorders including traumatic brain injury (“TBI”), acute concussions,
post concussion syndrome and multiple sclerosis. The company’s noninvasive
Electroceutical(R) therapeutic device, SofPulse(R), which uses pulsed
short-wave radiofrequency at 27.12 MHz, has been FDA cleared and CE marked for
the palliative treatment of soft-tissue injuries and postoperative pain and
edema and has CMS national coverage for the treatment of chronic wounds. The
company’s current portfolio of preclinical-stage Electroceuticals(R)
therapeutic devices addresses chronic kidney disease, liver-disease
nonalcoholic steatohepatitis (NASH), cardiovascular and peripheral artery
disease (PAD), and ischemic stroke. The company’s noninvasive, wearable
Electroceuticals(R) therapeutic devices work by restoring key electrochemical
processes that initiate anti-inflammatory and growth-factor cascades necessary
for healing to occur. For more information, visit the company’s website
at www.Endonovo.com.
NOTE TO INVESTORS: The latest news and updates
relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks
website applicable to all content provided by QS, wherever published or
re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment